Active	Status	Sponsor type	Region	Phase	Filter
2 Active 2 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oskooilar, Nader
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine Enrollment initiated in combination with Emgality for episodic migraine Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine	Completed	4	580	US	Galcanezumab, LY2951742, Rimegepant, Placebo	Eli Lilly and Company	Migraine, Episodic Migraine	05/23	05/23
Kim, Kristin
NCT05217927 / 2021-005239-22: Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens	Completed	4	698	Europe, Canada, US	Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing	Pfizer, Biohaven Pharmaceuticals Holding Company Limited, Pfizer Inc.	Migraine	10/24	12/24